Mad Money: Sell Block: Why Celgene's a Buy - Mad Cap Recap

FEATURED SLIDESHOW

  Who Is The Worst CEO?
Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
  nominations.

RECENT POSTS

Get stock and market information from Mad Money's Jim Cramer sent to your mobile phone.

Road Rules

Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

Watch the Videos

Text Size

Oct.26

11:39 AM ET

Friday, 26 Oct 2007

Sell Block: Why Celgene's a Buy

Posted By:Tom Brennan

Topics:Stock Picks | Stock Market

Companies:Stereotaxis Inc | Research in Motion Limited | Align Technology Inc | Hansen Medical, Inc.

Celgene, which is down $6, might seem to be the perfect candidate for the Sell Block, but it’s a buy as far as Cramer’s concerned.

The company reported a strong third quarter Thursday, but European sales of Revlimid, its blood cancer drug, weren’t good enough for Wall Street. Chief Operating Officer Bob Hugin told Cramer via phone that sales where “pretty solid,” but he knows analysts were expecting more.

Hugin said the problem was that Revlimid can be rolled out only one country at a time in Europe, and Celgene [CELG Loading... () ] started with Germany. Rollouts in France and Ireland are coming in the next couple of weeks, so the prospects are good for a strong European performance, he said.

Celgene “remains bankable,” Cramer said. He recommended buying a position in CELG if the stock is downgraded Friday.

As for stocks that should be sold, Cramer had to admit he made a huge mistake with Align Technology [ALGN Loading... () ], maker of Invisalign braces. Homegamers might remember he spotlighted the stock just last week. The stock dropped 34% in Thursday trading after lowering its guidance for the next quarter and announcing the departure of its chief financial officer.

Cramer can’t understand how a company can raise guidance for two quarters and then lower guidance for the next. He also found it strange that the CFO’s resignation would coincide with that revision. Something’s wrong with Align, and he doesn’t want investors anywhere near it.

Hansen Medical [HNSN Loading... () ] is also a sell. The stock is up $10 from where Cramer recommended it, so he recommended taking profits. A lot of people on the Street think Hansen is a takeover candidate because of its intellectual property agreement with Intuitive Surgical. Cramer doesn't think so - if Intuitive wanted to buy Hansen, they obviously wouldn't be selling their shares in the company. Others think that Hansen's stock will have the sort of run that Intuitive has been seeing, but Cramer doesn't buy that either; while Intuitive faces no competition, Hansen's got a solid competitor in Stereotaxis [STXS Loading... () ]. Take profits before they become losses, Cramer said.

Lastly, both Lululemon [LULU Loading... () ] and Research in Motion [RIMM Loading... () ] are up over 50% since Cramer recommended them. Don’t be a pig, he said. Take half off the table and let the rest ride.

Click for the rest of tonight's show

Questions for Cramer?

Questions, comments, suggestions for the Mad Money website?

Tools:

Print Email

Previous Post Back to Main Page

ADD COMMENTS